ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,808 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselTaysha Gene Therapies Switzerland GmbH
Taysha Gene Therapies Switzerland GmbH Logo
Verified· 2 sources

Taysha Gene Therapies Switzerland GmbH

Summary

About the company

Taysha Gene Therapies Switzerland GmbH is a biopharmaceutical company focused on discovering, developing and commercializing gene therapies for monogenic diseases of the central nervous system (CNS). Its lead clinical program targets Rett syndrome (TSHA-102), an intrathecally delivered AAV9 gene replacement therapy that incorporates a miRNA‑responsive auto‑regulatory element (miRARE) to regulate MECP2 expression.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Gene therapy for Rett syndrome (TSHA-102)
Gene therapy for Rett syndrome with TSHA-102 as a one-time, intrathecally administered AAV9 gene transfer therapy; clinical development to treat the genetic cause, using miRARE technology.
Clinical studies
Clinical studies of TSHA-102 in Rett syndrome, including the REVEAL Pivotal Trial, the ASPIRE Trial, and Phase 1/2 studies for pediatric, adolescent and adult patients.
Scientific information and publications
Scientific information on gene therapy and the AAV9 strategy, posters and publications on TSHA-102, as well as background material for professionals.
Expanded Access
Case-by-case review for Expanded Access requests for investigational therapies outside clinical trials, provided certain requirements are met.
Patient affairs and patient information
Patient affairs, information materials, community letters, resources and support for patients, family members and patient groups related to Rett syndrome and TSHA-102.

Knowledge

No knowledge articles yet

Once Taysha Gene Therapies Switzerland GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Taysha Gene Therapies Switzerland GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Taysha Gene Therapies Switzerland GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Taysha Gene Therapies Switzerland GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Aeschenvorstadt 4
4051 Basel

At a glance

Legal form
Limited Liability Company
UID
CHE-474.536.494
Founded
2021 · 5 years
Last commercial register change
November 23, 2021
Employees
1 to 10

Similar companies

AS
Autolus Switzerland AG
Basel
ET
EraCal Therapeutics AG
Basel
RA
RECORDATI AG
Basel
AT
ABBA Therapeutics AG
Basel
AP
Alpha-O Peptides AG
Riehen
AM
Altamira Medica AG
Basel
AB
Amyra Biotech AG
Basel
AB
AND Biotech AG
Basel